NB Health Laboratory (NBHL) has been conducting drug discovery programs for sleeping disorder with dementia and respiratory diseases such as lung inflammation, COPD and cancer. We are seeking pharmaceutical partners who are interested in our programs, worldwide. NBHL is flexible and will discuss a variety of collaborations to fund the development of the following programs.

**P001** a first in class monoclonal antibody targeted against a GPCR for a lipid mediator, for the treatment of lung cancer. The agent may also have potential in the treatment of immunological disease. Preclinical proof−of−concept in mouse studies of P 001 are ongoing. The Mab may also have utility in immunological diseases involving Th17 cells.

**P007** a monoclonal antibody targeted against a GPCR for a chemokine, for the treatment of fibrosis of the lung and kidney. Proof−of−concept preclinical studies are ongoing in animal models.

**P005** a small molecule highly selective kinase inhibitor. We are developing the P 005 for the treatment of sleep disorder in patients with dementia. Proof−of−concept preclinical evaluation of the agent has been conducted in animal models. The agent may also have utility in Alzheimer’s disease patients.

**Major Product Lines**: Supporting drug discovery. Pharmaceutical seeds

---

**Corporate Overview**

Address: 2–22, 7-chome, Ishiyama Higashi, Minami-ku, Sapporo, Hokkaido 0050850 JAPAN

Company Representative: Kiyoshi Takayama, Ph.D., president

Phone: +81-48-268-9739 Fax: +81-48-268-9736

URL: http://www.nbhl.co.jp

Foundation: July, 2006

Capital: 45,500,000 yen

Employees: 6

Category of Business: Pharmaceuticals

Business Overview: NBHL provides unique drug screening programs for age−related diseases such as vascular and respiratory diseases (COPD). NBHL Research platform covers biological assays (in vitro and in vivo) from target discovery to lead optimization. We also create functional monoclonal antibodies against membrane proteins including GPCR as lead antibodies using the unique screening methods. We provide original drug candidates (small molecules and Mabs) to pharmaceutical companies.

Contact: Kiyoshi Takayama, President of Saitama Lab.

E-mail: info@nbhl.co.jp